Date	e : 23. oktober 2024		
	r name: Kristine Bjørnda		
Mai	nuscript title: Spytkir	telinfektioner	
Mar	nuscript number (if known)):	
are re third comr list a The f	elated to the content of you parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	relationships/activities/interests listed below that means any relation with for-profit or not-for-profit tent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether to bu do so. ps/activities/interests as they relate to the current
perta antih	nins to the epidemiology of ypertensive medication, ev	hypertension, you should ven if that medication is n	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.
	m #1 below, report all supp r items, the time frame for		d in this manuscript without time limit. For all nonths.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan	•	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	⊠ None	
	etc.) No time limit for this		
	item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from	None	
	any entity (if not indicated in item #1 above).		
	,		
3	Royalties or licenses	None Non	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non-financial interests	⊠ None

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Date	0: 02 -14-1 2004		
		Mieleccione	
	•	telinfektioner	
Mar	nuscript number (if known)):	
are re third comr list a	elated to the content of you parties whose interests ma nitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	nins to the epidemiology of ypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Time	e frame: Since the initial plan		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	⊠ None	
	No time limit for this item.		
			Click TAB in last row to add extra rows
Time	e frame: past 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	None	
3	Royalties or licenses	None Non	

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non-financial interests	⊠ None

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Dat	e: 23. oktober 2024		
	Ir name: Andreas Lundh		
		talinfaktionar	
	•	telinfektioner	
ivia	nuscript number (if known):	
are r third comi list a	elated to the content of yo parties whose interests ma mitment to transparency ar relationship/activity/intere	ur manuscript. "Related" ay be affected by the cont nd does not necessarily in est, it is preferable that yo	
	ollowing questions apply to uscript only.	o the author's relationship	os/activities/interests as they relate to the <u>current</u>
perta antih In ite	nins to the epidemiology of hypertensive medication, ev	hypertension, you should yen if that medication is n port for the work reported	defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all months.
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
Tim	e frame: Since the initial plan	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
Tim 1	e frame: Since the initial plan All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	whom you have this relationship or indicate none (add rows as needed) ning of the work	(e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated in item #1 above).	whom you have this relationship or indicate none (add rows as needed) Ining of the work None	(e.g., if payments were made to you or to your institution)
Tim 2	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	whom you have this relationship or indicate none (add rows as needed) ming of the work None	(e.g., if payments were made to you or to your institution)

4	Consulting fees	⊠ None
5	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	None None
6	Payment for expert testimony	None
7	Support for attending meetings and/or travel	None
8	Patents planned, issued or pending	⊠ None
9	Participation on a Data Safety Monitoring Board or Advisory Board	None
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	None None
11	Stock or stock options	None
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	None None
13	Other financial or non-financial interests	⊠ None

Please place an "X" next to the following statement to indicate your agreement:

 \boxtimes I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal

Please save/export the filled in form as PDF before submitting it to Ug

	anoli M	Grants or contracts from	~ <
WALLS READ READ READ READ READ READ READ READ		e frame: past 36 months	шп
OLD DAY OF OUR OWNERS OF THE OWNER OF THE OWNER		-41a. 35 tice ionera) e	
Click TAB in last row to add extra ro		etc.) No time limit for this item.	ON
	anoN ⊠	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges,	I
		e frame: Since the initial plan	
Specifications/Comments (e.g., if payments were made to you or to your institution)	Name all entities with whom you have this relationship or indicate none (add rows as		
ot mentioned in the manuscript. d in this manuscript without time limit. For all	en if that medication is n oort for the work reported	ypertensive medication, ev	litn di r
d in this manuscript without time limit. For all	hypertension, you should en if that medication is n oort for the work reported	ains to the epidemiology of hypertensive medication, ev om #1 below, report all supp	he ert litn
d declare all relationships with manufacturers of ot mentioned in the manuscript. d in this manuscript without time limit. For all	ities/interests should be g hypertension, you should en if that medication is n	uscript only. author's relationships/activi ains to the epidemiology of hypertensive medication, ev em #1 below, report all supp	he ert litn
bs/activities/interests as they relate to the <u>currer</u> defined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript. ot mentioned in the manuscript.	ur manuscript. "Related" by the cont by the cont of does not necessarily in set, it is preferable that you the author's relationship hypertension, you should be gen if that medication is noort for the work reported out for the work reported	elated to the content of you parties whose interests may mitment to transparency and relationship/activity/interestrions apply to uscript only. Buthor's relationships/activity interestricts only. Buthor's relationships/activity of the epidemiology of the epidemiology of hypertensive medication, every man #1 below, report all supplement.	re i nirco omo st st st st st he nert he ert erti
means any relation with for-profit or not-for-pro- fent of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether ou do so. befined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.	we ask you to disclose all un manuscript. "Related" by the confud does not necessarily in st, it is preferable that you the author's relationship hypertension, you should be gen if that medication is not tor the work reported to the that medication is not to the work reported to the for the work reported to the forthe work reported to the forther work reported to the forther work work reported to the forther work work work work work work work wor	elated to the content of you parties whose interests may mitment to transparency and relationship/activity/interestrions apply to uscript only. Buthor's relationships/activity interestricts only. Buthor's relationships/activity of the epidemiology of the epidemiology of hypertensive medication, every man #1 below, report all supplement.	n th re i nircomo omo s ts s ts ner he ert ert erti
relationships/activities/interests listed below this means any relation with for-profit or not-for-professors any relation with for-profit or not-for-professor of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether on do so. Jefined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.	we ask you to disclose all un manuscript. "Related" by the confid does not necessarily in st, it is preferable that you the author's relationship hypertension, you should be gen if that medication is not the work reported for the work reported port for the work reported preserved prese	e interest of transparency, yelated to the content of you elated to the content of you parties whose interests maintment to transparency an telationship/activity/interecolowing questions apply to uscript only. Buthor's relationships/activity interecology of the epidemiology of any pertensive medication, every pertensive medication, every medication, e	Mary of the composition of the composition of the composition of the composition of the control
relationships/activities/interests listed below this means any relation with for-profit or not-for-professors any relation with for-profit or not-for-professor of the manuscript. Disclosure represents a dicate a bias. If you are in doubt about whether on do so. Jefined broadly. For example, if your manuscript declare all relationships with manufacturers of ot mentioned in the manuscript.	we ask you to disclose all un manuscript. "Related" by the confid does not necessarily in st, it is preferable that you the author's relationship hypertension, you should be gen if that medication is not the work reported for the work reported port for the work reported preserved prese	e interest of transparency, velated to the content of you elated to the content of you parties whose interests maintent to transparency antelationship/activity/intereducing questions apply to uscript only. Buthor's relationships/activity intereducing only. Buthor's relationships/activity of the epidemiology of hypertensive medication, every medicatio	Mass Mass Mass Mass Mass Mass Tax Samon Mass Tax Samon Mass Mass Mass Mass Mass Mass Mass Mas

Royalties or licenses

in item #1 above).

any entity (if not indicated

3

anoN ⊠

euon ⊠	Other financial or non- financial interests	13
anon ⊠	Receipt of equipment, materials, drugs, medical writing, gifts or other services	75
anoM ⊠	Stock or stock options	ττ
onon ⊠	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	OI
anon ⊠	Participation on a Data Safety Monitoring Board or Advisory Board	6
əuoN ⊠	Patents planned, issued or pending	8
anon ⊠	Support for attending levert travel	L
onoN ⊠	Payment for expert testimony	9
anon ⊠	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events	S
anoN ⊠	seef gnitluenoO	t

Please place an "X" next to the following statement to indicate your agreement:

I certify that I have answered every question and have not altered the wording of any of the questions on this form.

IMPORTANT for Ugeskrift for Læger & Danish Medical Journal Please save/export the filled in form as PDF before submitting it to Ugeskrift for Læger or Danish Medical Journal.